- Open Access
Capsid protein expression and adeno-associated virus like particles assembly in Saccharomyces cerevisiae
© Backovic et al.; licensee BioMed Central Ltd. 2012
Received: 23 March 2012
Accepted: 6 August 2012
Published: 11 September 2012
The budding yeast Saccharomyces cerevisiae supports replication of many different RNA or DNA viruses (e.g. Tombusviruses or Papillomaviruses) and has provided means for up-scalable, cost- and time-effective production of various virus-like particles (e.g. Human Parvovirus B19 or Rotavirus). We have recently demonstrated that S. cerevisiae can form single stranded DNA AAV2 genomes starting from a circular plasmid. In this work, we have investigated the possibility to assemble AAV capsids in yeast.
To do this, at least two out of three AAV structural proteins, VP1 and VP3, have to be simultaneously expressed in yeast cells and their intracellular stoichiometry has to resemble the one found in the particles derived from mammalian or insect cells. This was achieved by stable co-transformation of yeast cells with two plasmids, one expressing VP3 from its natural p40 promoter and the other one primarily expressing VP1 from a modified AAV2 Cap gene under the control of the inducible yeast promoter Gal1. Among various induction strategies we tested, the best one to yield the appropriate VP1:VP3 ratio was 4.5 hour induction in the medium containing 0.5% glucose and 5% galactose. Following such induction, AAV virus like particles (VLPs) were isolated from yeast by two step ultracentrifugation procedure. The transmission electron microscopy analysis revealed that their morphology is similar to the empty capsids produced in human cells.
Taken together, the results show for the first time that yeast can be used to assemble AAV capsid and, therefore, as a genetic system to identify novel cellular factors involved in AAV biology.
Adeno-associated Virus (AAV) of the Dependovirus genus is a member of the Parvoviridae, a family of small and the simple viruses, whose 4.7 kb single stranded DNA (ss-DNA) is enclosed in a non-enveloped, 20–25 nm icosahedral capsids[1, 2]. For more than 25 years, the AAV genome has been thought to contain two genes, rep and cap, corresponding to two open reading frames (ORFs) and coding for four Rep proteins that regulate replication and three VP proteins (subunits) that form capsids. Rep68 and 78 are transcribed from the p5 promoter and Rep52 and Rep40 from the p19 promoter. The p40 promoter regulates the transcription of the cap gene encoding for the VP1, VP2 and VP3 proteins that form the 60 subunit capsids in the proper stoichiometry 1:1:10. This precise VP1, 2 and 3 protein ratio is thought to be the consequence of the alternative splicing required for VP1 expression and the usage of an uncommon ACG site for VP2 translation initiation[3, 4]. Only recently, an alternative AAV ORF has been mapped in the cap gene and codes for the assembly activating protein (AAP) that promotes capsid assembly in 293 T cells. Rep68 and 78 participate in the AAV DNA replication and regulate transcription from AAV promoters and some host-cell promoters; Rep40 and 52 are involved in the generation and accumulation of single–stranded viral genomes from double stranded replication intermediates. The coding region of AAV genome is flanked by two 145 nucleotide long inverted terminal repeats (ITRs). The ITRs are the only cis-acting elements necessary for AAV replication, packaging and integration. AAV-based vectors have quickly gained great popularity in gene therapy applications owing to: (i) reduced ethical concerns regarding the nonpathogenic nature and limited viral sequences retained in vectors and (ii) favorable properties, such as high efficiency of transduction of post-mitotic tissues and the long-term persistence of transgene expression. The rising number of AAV vector-based gene therapy trials that require high vector doses, over 1013 genome copies (g.c.)/kg of body weight, resulted in a variety of currently existing systems for rAAV vectors’ production, based on mammalian and insect cell-factories. In view of developing a better rAAV production technology and creating a simple system for revealing still unknown aspects of AAV life cycle, we have recently established a novel, Saccharomyces cerevisiae - based recombinant system for ssDNA AAV2 genome formation from the circular vectors. To date, a great number of simple, single subunit virus/nucleocapsid-like particles (VLPs/NLPs) has been efficiently produced in yeast that therefore has a notable value in vaccine production technologies. Apart from offering low-cost and easy to scale-up production, the benefit of this microbial cell-factory is its intracellular environment, highly suitable for the most of metazoan posttranslational processing events, which are a prerequisite for complex multimeric protein interactions. Recently, Rotavirus-like particles were assembled and extracted from S. cerevisiae cells. To further explore usefulness of this microbial host, this work describes the permissiveness of S. cerevisiae intracellular environment to assembling of AAV type 2 capsids. With the purpose of finding the best expression system to assemble AAV VLPs in yeast cells, we expressed the three capsid proteins from their natural p40 promoter or from yeast promoters, in combination with, or without, plasmid expressing Rep proteins. Finally, the work demonstrates that AAV VLPs morphologically similar to those ones from mammalian or insect cells, can be assembled in the budding yeast Saccharomyces cerevisiae.
Materials and methods
All AAV-2 sequences in the following constructs derive from pSub201 plasmid which contains complete wild-type AAV-2 genome. YEplac181}, pYES2 (Invitrogen) and pGAD424 (Clontech) are vectors with LEU2 or URA3 genes for yeast selection. To make the plasmid YEplac.p40Cap construct, unmodified AAV2 Cap gene was cut out from pSub201 and cloned in YEplac181 vector, using Sal I and Xba I sites. For construction of the YEplacRepCap plasmid, the AAV2 genome without ITRs was cut out from pSub201 and cloned in the YEplac181 vector using Xba I restriction site. pYESIntronCap construct was made by cutting out AAV2 Intron + Cap sequence (without p40 promoter) from pSub201 and cloning this fragment in the multiple cloning site of pYES2 vector, using Hind III and Xba I restriction sites. To make the pYESCap plasmid, VP1 cDNA (map position 2203–4410 in wild-type AAV2 genome in the database, GenBank accession no. AF043303.1) was amplified by PCR from pSub201 using following primers:
5' - ctt ATGGCTGCCGATGGTTATCTT-3' and 5' - ctggTTACAGATTACGAGTCAGGTA −3.'
The sequence corresponding to the wild-type AAV2 genome is capitalized. The pYESVP1KM plasmid was constructed by cloning modified VP1 cDNA under Gal1 promoter. The VP1 cDNA was PCR amplified from pSub201vecotr using following primers:
5'-caggatcc aaaca ATGGCTGCCGAC GGTTATCTA CCC GATTGGCTC-3' and
Bam HI sites (at each primer end, underlined and bold letters) were introduced outside the VP1 expression cassette for cloning in pYES2 expression plasmid. Beside Bam HI restriction site, upper primer also included 5 nucleotide long yeast Kozak sequence (italicized letters) upstream to the VP1 ATG and three modifications (underlined letters) relative to the genuine VP sequence in the database. The sequence corresponding to the wt VP ORF is capitalized. After direct cloning in pYES2 Bam HI site, desired clone contained Kozak sequence upstream to the ATG start site and three mutations with respect to genuine AAV2 sequence. The first T to C mutation at position 11 eliminates an out-of frame ATG codon by creating an ACG triplet instead. The second modification is inactivation of the major AAV splice acceptor site, by substituting T to A at position 21 and A to C at position 24 (numbering is as for the sequence in the database).
Yeast strain, media
The strain RSY12 (MAT a leu2-3,112 his3-11,15 URA3::HIS3) has a complete deletion of URA3 gene which was replaced with the HIS3 gene. Complete (YPAD) and synthetic complete (SC) mediums were prepared according to standard protocols. Yeast was cultivated aerobically in flasks at 30°C under constant orbital shaking (180 rpm). All yeast cultures were started from a small inoculation (less than 100 μl per 50 ml of culture medium) of stationary phase yeast cells. After over-night growth, cells were collected at desired points of the growth cycle determined by absorbance at 600 nm (OD600): early exponential (log) growth phase of O.D600 0.7-1.0, mid-log phase yeast culture of OD600 3.5- 4.0 and early stationary phase O.D600 ~8.
The cap expressing plasmids YEplacRepCap, YEplacp40Cap, pYESCap and pYESIntronCap, were transformed in yeast cells either independently or in combination, using the standard high-efficiency, lithium chloride based method, using single-stranded DNA as a carrier. Single transformants were selected onto SC-uracil (SC-URA) or SC-leucine (SC-LEU) plates while double transformants were selected onto SC-uracil-leucine (SC-URA-LEU) plates. Monoclonal cultures were repeatedly grown under selection either in the solid or in the corresponding liquid medium. The AAV protein expression was induced with either 5% galactose or different glucose + galactose concentrations as stated in the results.
For analysis of AAV proteins by gel electrophoresis, we set up the novel protein extraction method named “Optimized post-alkaline” protein extraction, which consists of two cycles of extraction. Briefly, aliquots corresponding to 100–200 × 106 cells were subjected to the first round of extraction by the method published by Kushnirov with a small variation in the extraction buffer (50 mM TrisHCl pH6.8, 5% glycerol, 3% SDS, 5% β-mercaptoethanol). After centrifugation, the first protein extract named “extract 1” was ready for further analysis. The pellet was resuspended in harsh RIPA buffer (500 mM NaCl, 50 mM Tris–HCl, 1 mM EDTA, 1% Triton, 1% Deoxycholate (DOC), 1% SDS) and protein solubilization further assisted by sonication. After eliminating the cellular impurities, the resulting proteins fraction was named “extract 2”. Extracts 1 and 2 were analyzed by 10% SDS-PAGE polyacrylamide gel electrophoresis. Protein expression was analyzed by Western blot assay using previously described monoclonal antibodies: anti-Rep monoclonal mAb 303.9, anti-VP1, 2 mAb A69, anti-VP1, 2, 3 mAb B1 and anti-3 phosphoglycerate kinase (3PGK, Molecular Probes) as loading control. Like in other systems, for numeric estimation of VP protein stoichiometry we used band densitometry analysis performed by means of software Scion Image.
AAV VLP extraction
Aliquots corresponding to 25 ml of yeast culture in log-phase of growth (3 × 107 cells/ml) in medium containg 2% glucose were diluted 10 fold and re-grown on glucose for another 12–16 h until reached OD600 4 (mid-log phase). Then, cells were harvested, washed and inoculated in the induction media (e.g. 0.5% glucose +5% galactose). At different time points, cells were harvested, washed and further analysed. Samples of 10 g of yeast pellet were resuspended in 20 ml of DNS disruption buffer (500 mM NaCl, 10mMTris pH8, 1 mM EDTA, 0.3% NP-40, 0.3% DOC; protease-inhibitor cocktail supplemented) and homogenized by vigorous vortexing at 4°C with 400 nm glass beads. The crude lysate was cleared from cell-debris and undisrupted cells by quick-low speed centrifugation. The cleared lysate was then centrifuged at 20 000 × g, for 1 hour at 4°C ; the pellet was subjected to the second extraction performed in the same way as the first one, with additional 10 sonication cycles (15 sec on and 30 sec off; 15 microns amplitude) in order to enhance solubilization of yeast produced AAV VLPs. After sonication, the cell lysate was centrifuged again for 1 hour at 20,000 × g at 4°C for elimination of insoluble material. The supernatant was mixed with the first one and subjected to 200,000 × g ultracentrifugation at 4°C through 40% sucrose cushion (40% sucrose in TE-BSA buffer: 10 mM Tris pH8, 1 mM EDTA and 0.01%BSA) for 3 h. After the centrifugation, the pellet was resuspended in 5 ml resuspension buffer (150 mM NaCl, 10 mM Tris–HCl pH 8, 1 mM EDTA, 5 mM MgCl2), sonicated and left in agitation for 15 h at 4°C. To improve solubilization of assembly products, the mixture was treated with DNase (Benzonase purity grade I, Novagen) for 30 minuntes at 37°C. Finally, the suspension was cleared by a further centrifugation at 15000 × g for 10 minutes at 4°C. The supernatant was loaded on CsCl gradient. CsCl was added to the sample at final density of 1.4 g/cm3, and ultracentrifugation was performed at 39,000 rpm for 48 hours, at 18°C, in a SW40-Ti rotor. 12 fractions of 1.371 to 1.430 g/cm3 densities (refractometer readings) were collected, dialyzed against PBS buffer, and each fraction was analyzed for VP composition by Western blot.
Transmission electron microscopy
Fractions were placed on 200-mesh formvar carbon coated copper grids. The sample was stained with five drops of 2.5% (w/v) of uranyl acetate solution and incubated for 2 minutes at room temperature. The excess solution was removed by blotting the edge of each grid onto filter paper and the grid was air dried for 30 minutes. Samples were examined with a Jeol 100 SX transmission electron microscope.
Capsid protein expression from the AAV p40 promoter and influence of Rep proteins
Plasmids constructed in this study
wt cap sequence including p40promoter was cloned in YEplac181 vector containing 2μm as replication origin and LEU2 as selection marker
Entire wt AAV ORFs, rep and cap was cloned in YEplac181 vector containing 2 μm as replication origin and LEU2 as selection marker
Cap sequence including intron sequence (without p40) located upstream the start codon of VP1 was cloned downstream Gal1 promoter of pYES2 vector. The selection marker is URA3
Entire Cap sequence from start codon of VP1 to the VP3 stop codon was cloned downstream Gal1 promoter of pYES2 vector. The selection marker is URA3
VP1 coding region was cloned downstream Gal1 promoter of pYES2 vector. yeast Kozak-like element right upstream VP1 start site. Two mutations in major splice acceptor and a mutation in an out of frame ATG. The selection marker is URA3
In the natural background, the expression of VP proteins is regulated by Rep68 and 78 proteins through the p40 promoter activity and mRNA maturation. The first process is dependent on sequences associated with p5 and p19 promoter elements, the second one is achieved when the AAV2 intron element is paired to its natural promoter and extended polyadenylation signal. In order to assess if the expression of Rep could increase the expression of VP1, 2, and 3, we introduced rep and cap gene in their wild type genomic configuration into the yeast vector YEplac181, thus keeping p5, p19, p40, intron and the polyadenylation signal. The resulting plasmid was named YEplacRepCap (Figure1, scheme “b”). RSY12 cells carrying this construct were grown and collected at two different growth phases, mid-log and late-log phase, and respective protein extracts analyzed by Western blot for Rep and Cap protein expression. All the Rep proteins, namely Rep40, 52, 68 and 78 were expressed and achieved the maximal level at the late-log phase (Figure2B). Insoluble protein fraction (extract 2) was more abundant in all Rep protein species. To investigate the influence of Rep proteins upon the VP expression, we compared the Western blot results for VPs produced in these cells with the ones from YEplacp40Cap transformants which do not express Rep. VP3 was the only capsid protein detected without a notable difference in its intracellular level and distribution to extracts 1 and 2 (Figure2C), indicating that Rep proteins had no influence on VP expression in yeast.
Inducible Yeast Promoter for Regulation of AAV Structural Protein Expression
Studied of AAV protein expression in insect cell system demonstrated that the introduction of some modifications in the coding sequences could improve VP expression. So we made another pYES2-based construct, named pYESVP1KM (Figure1 scheme “e”) that lacks AAV intron and contains VP1 coding region downstream to pGal1 and yeast Kozak-like element right upstream of VP1 start site. In addition, we introduced two site specific mutations in the VP1 sequence: a mutation in the major AAV splice acceptor site to eliminate the possible splicing from the VP1 mRNA and an out-of-frame ATG mutation in the close proximity to VP1 translational start site to prevent interference with the choice of the right reading frame.
Western blot analysis of protein extracts from pYESVP1KM transformed cells showed that galactose induction caused gradual increase in VP1 protein expression with the highest level achieved after around 7 h of induction (Figure3B). VP1 was the only capsid protein detected in these cells. The majority of VP1 protein was recovered from insoluble fraction of the total cell proteins (extract 2, Figure3B).
Modulation of VP1/VP3 expression pattern as a prerequisite for efficient capsid assembly
Assembly and characterization of VLPs
Since both constructs used for VP1 and VP3 expression contained unmodified VP2 ORF, comprised in, and in frame with VP1 ORF, we were curious to investigate the origin of VP2 protein. To do this, yeast cells transformed with pYESVP1KM or YEplacRepCap, were induced and processed for ultracentrifugation as double-transformed yeast clones. The two corresponding pellet fractions were analyzed for VP proteins composition by Western blot (Figure6B, lanes 3 and 4). Total cell extracts were analyzed in parallel to monitor the relative intracellular levels of VPs (Figure6B, lanes 1 and 2). No VP2 was detected neither in the total protein extract derived from YEplacRepCap transformed cells (Figure6B, lane 1) nor in the one from the pYESVP1KM clones (Figure6B, lane 2). The VP composition in the ultracentrifugation pellet derived from YEplacRepCap clones (Figure6B, lane 3) was identical to the one in its total cell extract: the only protein detectable was VP3. In the pellet from pYESVP1KM–transformed cells, all three VP proteins were detected, suggesting that VP2 and VP3 are synthesized from this construct at low levels (Figure6B, lane 4). The relative VP1:VP2:VP3 ratio in this pellet was 1: 0.25: 0.9. As expected, the relative amount of VP2 was lower than VP1, whereas the level of VP3 was almost equal to VP1 protein, in divergence with its low overall intracellular level, undetectable by Western blot (Figure6B, lane 2). This result suggest that even when the concentration of VP was too small for their detection by Western blot, they could assemble into VLPs.
To finally demonstrate that yeast supports AAV capsid assembly, small aliquots of fractions of similar densities derived from CsCl gradient fractionation were mixed and analyzed in transmission-electron microscopy (TEM) for the presence of capsid-like structures (Figure7B). Capsid-like structures were observed in f8-f11 fractions, in the density range of 1.386-1.394 g/cm3, containing the three capsid proteins in the relative frequencies similar to the ones of wt AAV-2 capsids. Figure7B-i shows that yeast-cell derived capsid-like structures observed in fraction f8 combined with f9 (f8 + f9) were morphologically similar to the ones obtained from 293 T cells (Figure7B-ii, a kind gift from J. Kleinschmidt). The density of capsid positive fractions is not corresponding to the expected ones for empty AAV capsids produced in mammalian cells (1.32-1.35 g/cm 3 )[19, 31], but is very similar to the density reported for AAV empty particles from insect cells (1.38 g/cm3).
To support electron microscopy results, the “VLP-positive” fractions with similar densities were combined resulting in f3 + 4, f10 + f11, f8 + f9 fractions and analyzed in Dot-Blot assay to assess immunoreactivity of yeast-derived particles with anti-capsid A20 antibody. A20 is a widely used monoclonal antibody which specifically binds a conformational AAV-2 capsid epitope and does not recognize native capsid subunits and other assembly intermediates. Interestingly, all three fractions showed reactivity to A20 antibody, even f3 + 4 fraction which in western blot analysis showed low level of VP2 and VP3 and VP1 was not detected (Figure7A). The highest concentration of A20-reactive virus-like particle was observed in f8 + f9 fraction (Figure7C). This result suggests that the VP proteins assembled in the correct way in yeast.
In line with raising importance of yeast cell-factories in production of VLPs used in vaccinology, diagnostics, sero-epidemiology, nanotechnology and gene transfer, we created the S. cerevisiae expression system for studying the permissiveness of its intracellular background to self-assembly of AAV2 capsid proteins in virus-like particles with properties similar to those of AAV capsids produced in mammalian or insect cells. In mammalian cells, the optimal ratio of AAV VPs proteins to obtain high amounts of particles was achieved by placing the rep ORF under a strong promoter and the cap ORF under the control of its natural promoter (p40). In insect cells, high AAV titers have been obtained using specific baculovirus promoters.
In order to achieve the best VP protein ratio for the correct assembly in yeast, two requirements has to be satisfied: the simultaneous expression of at least two out of three AAV structural proteins, VP1 and VP3 and the intracellular stoichiometry of these proteins in yeast cells should be similar to that one found in the particles derived from mammalian or insect cells. We constructed one plasmid carrying modified AAV2 Cap ORF under inducible yeast promoter Gal1and the another vector expressing VP3 from the genuine AAV cap gene under its cognate p40 promoter. VP3 protein expression from AAV p40 promoter in yeast cells resembled the expression profile of yeast glycolytic-promoters, characterized by the positive correlation with the cell growth rate during glucose-based growth.The best results in terms of “optimal” VP1:VP3 ratio and experimental reproducibility were obtained when glucose was kept at low concentration (0.5%) in the galactose rich (5%) medium. The ratio of VP proteins in cell extracts has been suggested to correlate with VLP composition indicating that the optimal level of proteins is required for the VLP correct assembly. Therefore, after 4.5 hour induction, we have obtained the best VP1:VP3 ratio and we were able to extract VLPs from yeast. Although the CsCl fractions did not have the expected buoyant density, all the VPs proteins were detected and the VLPs were composed of VP1, VP2 and VP3. The buoyant density of infectious AAV particles is reported to range from 1.39 to 1.42 g/cm3. Empty or partial empty AAV particles have been shown to have a density corresponding to 1.32 and 1.35 g/cm3. On the other hand, AAV empty particles purified from insect cells have a density of 1.38 g/cm3 that is not very different from the buoyant density of VLPs from yeast. These light particles appear empty at the electron microscope and have been reported to have either no DNA or DNA of less that genome length; the density of the AAV particles is generally correlated with the size of the encapsidated DNA. We can suppose that higher density of “empty” VLPs from yeast is due to the presence of small yeast DNA fragments inside. This is very difficult to demonstrate since we have a low amount of CsCl fractions because most VLPs remained in the pellet. We have further characterized by electron microscopy VLP fractions with buoyant densities ranging from 1.386 to 1.392 g/cm3. Results indicated that the VLPs from yeast are morphologically and immunologically similar (reactivity to A20 antibody) to the particles extracted from human cells (see Figure7B and C). Our study provides the first experimental evidence that the yeast Saccharomyces cerevisiae is able to form AAV VLPs. However, a certain amount of VPLs was not recovered after ultracentifugation. A similar situation was seen in the first baculovirus-insect cell VP-expression system made by Ruffing et al. where the three VPs were expressed from separated ORFs (cDNAs), each one carrying mutations in other two VP-start codons. Moreover, in HeLa cells it has been observed that not assembled VP monomers can associate with cellular structures has been previously documented in vitro and.
This work demonstrated that S. cerevisiae assembles AAV proteins into VLPs and opens new frontiers towards the use of yeast in the rAAV production. Together with our pioneer demonstration of ss rAAV genomes production in this microbial system, it leads the future research toward studying yeast permissiveness to packaging of ss rAAV genomes in preformed capsids.
We thank Robert Schiestl for the yeast strain. We also are grateful to Jürgen Kleinschmidt for helpful suggestions and for sending the purified AAV vectors. We would like to dedicate this paper to our colleague and friend Arturo Falaschi who suddenly died on the 2nd of June 2010. He really believed in this project and strongly stimulated us to go on with experiments. The work was supported by the Grant n. GGP09166 assigned from Telethon-Italy to AG.
- Lukashov VV, Goudsmit J: Evolutionary relationships among parvoviruses: virus-host coevolution among autonomous primate parvoviruses and links between adeno-associated and avian parvoviruses. J Virol. 2001, 75 (6): 2729-2740. 10.1128/JVI.75.6.2729-2740.2001View ArticleGoogle Scholar
- Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M: Recent developments in adeno-associated virus vector technology. J Gene Med. 2008. 10.(7): 717-733.View ArticleGoogle Scholar
- Van Vliet KM, Blouin V, Brument N, Agbandje-McKenna M, Snyder RO: The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol. 2008, 437: 51-91. 10.1007/978-1-59745-210-6_2View ArticleGoogle Scholar
- Becerra SP, Koczot F, Fabisch P, Rose JA: Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript. J Virol. 1988, 62 (8): 2745-2754.Google Scholar
- Sonntag F, Schmidt K, Kleinschmidt JA: A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A. 2010. 10. (22).View ArticleGoogle Scholar
- Wu Z, Asokan A, Samulski RJ: Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther. 2006, 14 (3): 316-327. 10.1016/j.ymthe.2006.05.009View ArticleGoogle Scholar
- Qiao C, Li J, Zheng H, Bogan J, Yuan Z, Zhang C, Bogan D, Kornegay J, Xiao X: Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther. 2009, 20 (1): 1-10. 10.1089/hum.2008.135View ArticleGoogle Scholar
- Cervelli T, Backovic A, Galli A: Formation of AAV single stranded DNA genome from a circular plasmid in Saccharomyces cerevisiae. PLoS One. 2011, 6 (8): e23474- 10.1371/journal.pone.0023474View ArticleGoogle Scholar
- Quartley E, Alexandrov A, Mikucki M, Buckner FS, Hol WG, DeTitta GT, Phizicky EM, Grayhack EJ: Heterologous expression of L. major proteins in S. cerevisiae: a test of solubility, purity, and gene recoding. J Struct Funct Genomics. 2009. 10.(3): 233-247.View ArticleGoogle Scholar
- Rodriguez-Limas WA, Tyo KE, Nielsen J, Ramirez OT, Palomares LA: Molecular and process design for rotavirus-like particle production in Saccharomyces cerevisiae. Microb Cell Fact. 2011. 10. 33.View ArticleGoogle Scholar
- Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A. 1982, 79 (6): 2077-2081. 10.1073/pnas.79.6.2077View ArticleGoogle Scholar
- Gietz RD, Sugino A: New yeast-Escherichia coli shuttle vectors constructed with in vitro mutagenized yeast genes lacking six-base pair restriction sites. Gene. 1988, 74 (2): 527-534. 10.1016/0378-1119(88)90185-0View ArticleGoogle Scholar
- Schiestl RH, Petes TD: Integration of DNA fragments by illegitimate recombination in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 1991, 88 (17): 7585-7589. 10.1073/pnas.88.17.7585View ArticleGoogle Scholar
- Schiestl RH, Dominska M, Petes TD: Transformation of Saccharomyces cerevisiae with nonhomologous DNA: illegitimate integration of transforming DNA into yeast chromosomes and in vivo ligation of transforming DNA to mitochondrial DNA sequences. Mol Cell Biol. 1993, 13 (5): 2697-2705.View ArticleGoogle Scholar
- Kushnirov VV: Rapid and reliable protein extraction from yeast. Yeast. 2000, 16 (9): 857-860. 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-BView ArticleGoogle Scholar
- Wistuba A, Kern A, Weger S, Grimm D, Kleinschmidt JA: Subcellular compartmentalization of adeno-associated virus type 2 assembly. J Virol. 1997, 71 (2): 1341-1352.Google Scholar
- Wobus CE, Hugle-Dorr B, Girod A, Petersen G, Hallek M, Kleinschmidt JA: Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J Virol. 2000, 74 (19): 9281-9293. 10.1128/JVI.74.19.9281-9293.2000View ArticleGoogle Scholar
- Aucoin MG, Perrier M, Kamen AA: Critical assessment of current adeno-associated viral vector production and quantification methods. Biotechnol Adv. 2008, 26 (1): 73-88. 10.1016/j.biotechadv.2007.09.001View ArticleGoogle Scholar
- Grimm D, Kern A, Pawlita M, Ferrari F, Samulski R, Kleinschmidt J: Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther. 1999, 6 (7): 1322-1330. 10.1038/sj.gt.3300946View ArticleGoogle Scholar
- Kronenberg S, Kleinschmidt JA, Bottcher B: Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2001, 2 (11): 997-1002. 10.1093/embo-reports/kve234View ArticleGoogle Scholar
- Girod A, Wobus CE, Zadori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M: The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002, 83 (Pt 5): 973-978.View ArticleGoogle Scholar
- Romanos MA, Scorer CA, Clare JJ: Foreign gene expression in yeast: a review. Yeast. 1992, 8 (6): 423-488. 10.1002/yea.320080602View ArticleGoogle Scholar
- Qiu J, Pintel D: Processing of adeno-associated virus RNA. Front Biosci. 2008, 13: 3101-3115. 10.2741/2912View ArticleGoogle Scholar
- Qiu J, Pintel DJ: The adeno-associated virus type 2 Rep protein regulates RNA processing via interaction with the transcription template. Mol Cell Biol. 2002, 22 (11): 3639-3652. 10.1128/MCB.22.11.3639-3652.2002View ArticleGoogle Scholar
- Kim MD, Lee TH, Lim HK, Seo JH: Production of antithrombotic hirudin in GAL1-disrupted Saccharomyces cerevisiae. Appl Microbiol Biotechnol. 2004, 65 (3): 259-262.Google Scholar
- Friedl AA, Kiechle M, Maxeiner HG, Schiestl RH, Eckardt-Schupp F: Ty1 integrase overexpression leads to integration of non-Ty1 DNA fragments into the genome of Saccharomyces cerevisiae. Mol Genet Genomics. 2010, 284 (4): 231-242. 10.1007/s00438-010-0561-4View ArticleGoogle Scholar
- Grieger JC, Johnson JS, Gurda-Whitaker B, Agbandje-McKenna M, Samulski RJ: Surface-exposed adeno-associated virus Vp1-NLS capsid fusion protein rescues infectivity of noninfectious wild-type Vp2/Vp3 and Vp3-only capsids but not that of fivefold pore mutant virions. J Virol. 2007, 81 (15): 7833-7843. 10.1128/JVI.00580-07View ArticleGoogle Scholar
- Warrington KH: Gorbatyuk OS, Harrison JK, Opie SR, Zolotukhin S, Muzyczka N: Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol. 2004, 78 (12): 6595-6609. 10.1128/JVI.78.12.6595-6609.2004View ArticleGoogle Scholar
- Urabe M, Ding C, Kotin RM: Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther. 2002, 13 (16): 1935-1943. 10.1089/10430340260355347View ArticleGoogle Scholar
- Demir O: Aksan Kurnaz I: An integrated model of glucose and galactose metabolism regulated by the GAL genetic switch. Comput Biol Chem. 2006, 30 (3): 179-192. 10.1016/j.compbiolchem.2006.02.004View ArticleGoogle Scholar
- Tenenbaum L, Lehtonen E, Monahan PE: Evaluation of risks related to the use of adeno-associated virus-based vectors. Curr Gene Ther. 2003, 3 (6): 545-565. 10.2174/1566523034578131View ArticleGoogle Scholar
- Negrete A, Kotin RM: Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology. Brief Funct Genomic Proteomic. 2008, 7 (4): 303-311. 10.1093/bfgp/eln034View ArticleGoogle Scholar
- Grimm D, Kern A, Rittner K, Kleinschmidt JA: Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther. 1998, 9 (18): 2745-2760. 10.1089/hum.1998.9.18-2745View ArticleGoogle Scholar
- Virag T, Cecchini S, Kotin RM: Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther. 2009, 20 (8): 807-817. 10.1089/hum.2009.092View ArticleGoogle Scholar
- Brauer MJ, Huttenhower C, Airoldi EM, Rosenstein R, Matese JC, Gresham D, Boer VM, Troyanskaya OG, Botstein D: Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol Biol Cell. 2008, 19 (1): 352-367. 10.1091/mbc.E07-08-0779View ArticleGoogle Scholar
- Hoque M, Shimizu N, Ishizu K, Yajima H, Arisaka F, Suzuki K, Watanabe H, Handa H: Chimeric virus-like particle formation of adeno-associated virus. Biochem Biophys Res Commun. 1999, 266 (2): 371-376. 10.1006/bbrc.1999.1831View ArticleGoogle Scholar
- de la Maza LM, Carter BJ: Molecular structure of adeno-associated virus variant DNA. J Biol Chem. 1980, 255 (7): 3194-3203.Google Scholar
- Ruffing M, Zentgraf H, Kleinschmidt JA: Assembly of virus like particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J Virol. 1992, 66 (12): 6922-6930.Google Scholar
- Steinbach S, Wistuba A, Bock T, Kleinschmidt JA: Assembly of adeno-associated virus type 2 capsids in vitro. J Gen Virol. 1997, 78 (Pt 6): 1453-1462.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.